Linked Life Data

16797106

Source:http://linkedlifedata.com/resource/pubmed/id/16797106

Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:16797106rdf:typepubmed:Citationlld:pubmed
pubmed-article:16797106lifeskim:mentionsumls-concept:C0038172lld:lifeskim
pubmed-article:16797106lifeskim:mentionsumls-concept:C0205103lld:lifeskim
pubmed-article:16797106lifeskim:mentionsumls-concept:C0017953lld:lifeskim
pubmed-article:16797106lifeskim:mentionsumls-concept:C0030956lld:lifeskim
pubmed-article:16797106lifeskim:mentionsumls-concept:C0042313lld:lifeskim
pubmed-article:16797106lifeskim:mentionsumls-concept:C0683598lld:lifeskim
pubmed-article:16797106lifeskim:mentionsumls-concept:C1136254lld:lifeskim
pubmed-article:16797106lifeskim:mentionsumls-concept:C0681814lld:lifeskim
pubmed-article:16797106lifeskim:mentionsumls-concept:C0205195lld:lifeskim
pubmed-article:16797106pubmed:issue11lld:pubmed
pubmed-article:16797106pubmed:dateCreated2006-10-23lld:pubmed
pubmed-article:16797106pubmed:abstractTextAn experimental study has been performed to compare the in vitro activity and the in vivo efficacy of magainin II and cecropin A, two alpha-helical antimicrobial peptides, and vancomycin against Staphylococcus aureus with intermediate resistance to glycopeptides. In vitro experiments included MIC determination, time-kill and synergy studies. For in vivo studies, a mouse model of staphylococcal sepsis has been used. Main outcome measures were: lethality, quantitative blood cultures and detection of TNF-alpha and interleukin-6 (IL-6) plasma levels. Combinations of alpha-helical antimicrobial peptides showed in vitro synergistic interaction. Significant increase in efficacy was also observed in vivo: combined-treated groups had significant lower bacteremia when compared to single-treated groups. Magainin II combined with vancomycin exhibited the highest efficacy on all main outcome measurements. These results highlight the potential usefulness of these combinations and provide future therapeutic alternative in infections due to glycopeptides resistant staphylococci in the coming years.lld:pubmed
pubmed-article:16797106pubmed:languageenglld:pubmed
pubmed-article:16797106pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:16797106pubmed:citationSubsetIMlld:pubmed
pubmed-article:16797106pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:16797106pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:16797106pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:16797106pubmed:statusMEDLINElld:pubmed
pubmed-article:16797106pubmed:monthNovlld:pubmed
pubmed-article:16797106pubmed:issn0196-9781lld:pubmed
pubmed-article:16797106pubmed:authorpubmed-author:CirioniOscarOlld:pubmed
pubmed-article:16797106pubmed:authorpubmed-author:GiacomettiAnd...lld:pubmed
pubmed-article:16797106pubmed:authorpubmed-author:GhiselliRober...lld:pubmed
pubmed-article:16797106pubmed:authorpubmed-author:MocchegianiFe...lld:pubmed
pubmed-article:16797106pubmed:authorpubmed-author:OrlandoFioren...lld:pubmed
pubmed-article:16797106pubmed:authorpubmed-author:SabaVittorioVlld:pubmed
pubmed-article:16797106pubmed:authorpubmed-author:ScaliseGiorgi...lld:pubmed
pubmed-article:16797106pubmed:authorpubmed-author:SilvestriCarm...lld:pubmed
pubmed-article:16797106pubmed:authorpubmed-author:ChiodiLeonard...lld:pubmed
pubmed-article:16797106pubmed:authorpubmed-author:VittoriaAgnes...lld:pubmed
pubmed-article:16797106pubmed:issnTypePrintlld:pubmed
pubmed-article:16797106pubmed:volume27lld:pubmed
pubmed-article:16797106pubmed:ownerNLMlld:pubmed
pubmed-article:16797106pubmed:authorsCompleteYlld:pubmed
pubmed-article:16797106pubmed:pagination2600-6lld:pubmed
pubmed-article:16797106pubmed:meshHeadingpubmed-meshheading:16797106...lld:pubmed
pubmed-article:16797106pubmed:meshHeadingpubmed-meshheading:16797106...lld:pubmed
pubmed-article:16797106pubmed:meshHeadingpubmed-meshheading:16797106...lld:pubmed
pubmed-article:16797106pubmed:meshHeadingpubmed-meshheading:16797106...lld:pubmed
pubmed-article:16797106pubmed:meshHeadingpubmed-meshheading:16797106...lld:pubmed
pubmed-article:16797106pubmed:meshHeadingpubmed-meshheading:16797106...lld:pubmed
pubmed-article:16797106pubmed:meshHeadingpubmed-meshheading:16797106...lld:pubmed
pubmed-article:16797106pubmed:meshHeadingpubmed-meshheading:16797106...lld:pubmed
pubmed-article:16797106pubmed:meshHeadingpubmed-meshheading:16797106...lld:pubmed
pubmed-article:16797106pubmed:meshHeadingpubmed-meshheading:16797106...lld:pubmed
pubmed-article:16797106pubmed:meshHeadingpubmed-meshheading:16797106...lld:pubmed
pubmed-article:16797106pubmed:meshHeadingpubmed-meshheading:16797106...lld:pubmed
pubmed-article:16797106pubmed:meshHeadingpubmed-meshheading:16797106...lld:pubmed
pubmed-article:16797106pubmed:meshHeadingpubmed-meshheading:16797106...lld:pubmed
pubmed-article:16797106pubmed:meshHeadingpubmed-meshheading:16797106...lld:pubmed
pubmed-article:16797106pubmed:year2006lld:pubmed
pubmed-article:16797106pubmed:articleTitleExperimental study on the efficacy of combination of alpha-helical antimicrobial peptides and vancomycin against Staphylococcus aureus with intermediate resistance to glycopeptides.lld:pubmed
pubmed-article:16797106pubmed:affiliationInstitute of Infectious Diseases and Public Health, Università Politecnica delle Marche, Clinica delle Malattie Infettive, c/o Ospedali Riuniti Ancona, Via Conca 71, 60200 Ancona AN, Italy. anconacmi@interfree.itlld:pubmed
pubmed-article:16797106pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:16797106pubmed:publicationTypeResearch Support, Non-U.S. Gov'tlld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:16797106lld:pubmed